13/02/2026
Team PHD proudly participated in the Health Disparities Symposium held January 23–26, 2026, in Washington, DC, joining national leaders and health equity advocates to advance meaningful dialogue on chronic disease management and strengthen community‑centered care. As part of these conversations, we emphasized the critical role of pharmacogenomic (PGx) testing in addressing long‑standing inequities in treatment outcomes—particularly within minority communities.
PGx testing offers a powerful opportunity to move beyond one‑size‑fits‑all prescribing by identifying how an individual’s genetic makeup influences their response to medications. This is especially important for Black, Hispanic, Asian, Indigenous, and other underserved populations who have historically been underrepresented in clinical research. Many widely used medications were developed and validated in non‑diverse populations, which means their effectiveness and side‑effect risks can differ significantly across ethnic groups.
By integrating PGx testing into routine care, we can help reduce adverse drug reactions, improve treatment precision, and empower patients with knowledge that supports better health decisions. Most importantly, PGx testing serves as a meaningful step toward closing gaps in chronic disease management and ensuring that every community—regardless of background—benefits from the promise of personalized medicine.
Team PHD remains committed to advancing equitable, data‑driven solutions that uplift the communities most impacted by health disparities and bring us closer to a truly inclusive healthcare system.
